MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates

Go back to MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates
(NASDAQ: INKT) Delayed: 10.55 -0.16 (1.49%)
Previous Close $10.71    52 Week High $ 
Open $10.75    52 Week Low $ 
Day High $11.40    P/E N/A 
Day Low $10.51    EPS $ 
Volume 10,363